Fujifilm Diosynth to create biocampus in the UK

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/champc)
(Image: Getty/champc)

Related tags: Fujifilm diosynth biotechnologies, Fujifilm, facility

Fujifilm Diosynth announced plans to build a research center in the UK to answer growing demand in services for biologics, vaccines, and gene therapies development.

Located in Billingham, UK, the research center, known as BioCampus, will include a 42,000-square-foot office space, which is expected to house approximately 250 of the company’s existing employees, with an additional 50 people to be hired.

The site will have the potential to be expanded in the future with additional R&D laboratories or manufacturing facilities.

The project will see Fujifilm Diosynth Biotechnologies invest up to £14.5m ($17.11m), utilizing funding by the Tees Valley Mayor and Combined Authority, as well as from the UK government’s Local Growth Fund.

By building the new facility, Fujifilm Diosynth expects to meet the growing demand for its portfolio of partner programs, including development and manufacturing services of biologics, vaccines and gene therapies, the company stated.

Paul Found, the company’s chief operating officer, stated that the BioCampus will enable Fujifilm Diosynth to significantly enhance the quality of the working environment for its employees.

Construction of the BioCampus is expected to be completed by March 2021.

Related news

Show more

Related products

show more

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Blazar™ Platform: Rodent Virus Panel

Blazar™ Platform: Rodent Virus Panel

Viral Safety for mAb: Prevent, Detect, Remove | 16-Nov-2020 | Technical / White Paper

We have a long history of developing innovative molecular technologies for cell line characterization and lot release testing for the biopharmaceutical...

Monitoring SARS-CoV-2 interaction with ACE2

Monitoring SARS-CoV-2 interaction with ACE2

Take the Right Path Upstream with MilliporeSigma | 02-Nov-2020 | Technical / White Paper

In this technical note, we investigate the interactions between the following: The spike glycoprotein binding with ACE2, Spike glycoprotein and anti-spike...

Related suppliers

Follow us

Products

View more

Webinars